THE ROLE OF AI ENHANCING DRUG SAFETY FOCUS ON DRUG-DRUG INTERACTIONS

Ms.Eshika A.Deshmukh , Dr. S.G.Jawarkar ,Ms.Dhanshri Bhonde,

Ms.Diksha Patil

Vidyabharati college of pharmacy, AMARAVTI

Abstract

Drug safety remains a critical component of modern healthcare, and Drug-Drug Interactions (DDIs) represent a major preventable cause of adverse drug reactions. Traditional methods for identifying DDIs such as clinical trials, spontaneous reporting systems, and manual literature review are often limited by underreporting, high complexity, and delayed detection. Artificial Intelligence (AI) has emerged as a powerful tool capable of overcoming these limitations by analysing large, diverse biomedical datasets and identifying hidden patterns associated with potential interactions. Recent advancements in machine learning, deep learning, graph-based modelling, and natural language processing have significantly improved the accuracy and efficiency of DDI prediction.

This review provides an overview of the role of AI in enhancing drug safety, describing the major computational techniques used for DDI prediction and the fundamental data sources that support AI-driven pharmacovigilance. Key applications and case studies highlight AI's growing utility in early risk detection, personalized interaction assessment, and automated safety surveillance. Despite these advancements, challenges such as data quality issues, algorithmic bias, lack of transparency, and limited clinical validation continue to restrict widespread implementation. Future developments including explainable AI, federated learning, real-time decision support systems, and multi-omics integration are expected to strengthen predictive pharmacovigilance and support safer therapeutic decisions. Overall, the integration of AI into DDI prediction represents a promising step toward proactive, efficient, and patient-centred drug safety monitoring.

Keywords: -

Artificial Intelligence, Drug–Drug Interactions, Pharmacovigilance, Machine Learning, Deep Learning, Adverse Drug Reactions,

1. Introduction:

Drug safety is fundamental to ensuring effective pharmacotherapy and patient welfare. Adverse drug reactions (ADRs) contribute significantly to hospitalization, therapeutic failures, and healthcare costs. Drug-Drug Interactions (DDIs), which occur when one drug modifies the activity or effect of another, account for a large proportion of preventable ADRs. With the growing use of polypharmacy, especially among elderly and chronically ill patients, the risk of DDIs has risen considerably.

Conventional approaches to identifying DDIs, such as in vitro experiments, clinical trials, and post-marketing surveillance systems, often fall short due to their limited scope, time-consuming nature, and inability to detect rare or complex interactions. This has created a need for more advanced, efficient, and predictive methods.

In recent years, Artificial Intelligence (AI) has emerged as a transformative tool capable of addressing these challenges. By utilizing techniques such as Machine Learning (ML), Deep Learning (DL), and Natural Language Processing (NLP), AI can analyze large and diverse biomedical datasets, uncover hidden patterns, and predict potential interactions long before they appear in clinical settings.

AI-driven models can integrate information from electronic health records (EHRs), scientific literature, adverse event databases, and chemical or biological drug properties, enabling earlier detection of DDIs and enhancing pharmacovigilance efforts. As a result, AI is reshaping drug safety monitoring by offering faster, more accurate, and more comprehensive risk assessment compared to traditional methods. The growing adoption of intelligent computational systems marks a shift toward proactive drug safety evaluation and highlights the expanding role of AI in safeguarding patient health.

Recent research and regulatory insights increasingly demonstrate that AI has the capability to transform pharmacovigilance from a predominantly reactive process into a proactive and predictive system. Advanced AI algorithms including Gradient Boosting models, Convolutional Neural Networks (CNNs), and Long Short-Term Memory (LSTM) networks have shown strong performance in identifying adverse drug reactions using both structured clinical records and unstructured patient-generated data.

2. Artificial Intelligence and Its Role in Drug Safety

Artificial Intelligence (AI) refers to computational systems that can simulate human reasoning and learning. Within the pharmaceutical sciences, AI is widely applied for:

- Drug discovery and repurposing
- Toxicity and side effect prediction
- Clinical decision support systems (CDSS)
- Post-marketing safety monitoring



Fig-1: Role of AI in Drug Safety

AI-based models can process structured and unstructured data from electronic health records (EHRs), biomedical literature, and adverse event databases. This allows for predictive pharmacovigilance, identifying potential drug safety risks before they manifest in clinical practice.

Machine Learning (ML), Deep Learning (DL), and Natural Language Processing (NLP) are the primary AI techniques being integrated into pharmacovigilance. ML algorithms can identify complex and nonlinear patterns associated with adverse drug reactions (ADRs), while DL architectures such as Convolutional Neural Networks (CNNs) and Long Short-Term Memory (LSTM) networks have demonstrated excellent performance in predicting ADRs from both structured clinical data and unstructured patient-generated sources.

NLP allows automated extraction of safety information from text-based materials such as biomedical literature, social media posts, ICSRs (Individual Case Safety Reports), and clinician narratives, improving the detection of early safety signals that might otherwise be overlooked.

Global organizations, including the World Health Organization (WHO), acknowledge AI's growing role in strengthening pharmacovigilance practices. AI enhances drug safety monitoring by automating case processing, improving data accuracy, identifying unseen correlations, reducing processing time, and enabling more proactive safety surveillance.

Several studies show that AI-driven models outperform traditional signal detection techniques and can identify rare or emerging drug–drug interactions and ADR patterns earlier in the drug lifecycle.

3. Overview of Drug–Drug Interactions (DDIs)

Drug-Drug Interactions (DDIs) occur when the presence of one medication modifies the effect, metabolism, or safety profile of another. These interactions can either enhance or diminish a drug's therapeutic effect or increase the likelihood of adverse drug reactions (ADRs). DDIs represent a major and preventable contributor to medication-related harm, especially among older adults and patients receiving multiple medications. As polypharmacy becomes increasingly common, the clinical importance of identifying and preventing DDIs has grown considerably.



Fig-2: Drug-Drug interactions

- DDIs are broadly divided into **pharmacokinetic** and **pharmacodynamic** interactions.

Pharmacokinetic interactions involve changes in drug absorption, distribution, metabolism, or excretion (ADME). For example, enzyme inducers such as rifampicin can accelerate the metabolism of co-administered drugs, reducing their therapeutic effect, while inhibitors like ketoconazole may increase drug concentration and toxicity.

- **Absorption:**
  Changes in gastric pH, chelation, or gut motility can alter drug uptake. *Example:* Antacids containing magnesium or aluminium can reduce the absorption of tetracyclines (Goodman & Gilman, 2018).

- **Distribution:**
  Competition for plasma protein binding alters active drug levels. *Example:* Warfarin displacement by NSAIDs increases bleeding risk.

- **Metabolism:**
  Cytochrome P450 (CYP) enzyme induction or inhibition is the most common mechanism.

- **Excretion:**
  Medications may compete for renal tubular secretion or affect renal blood flow. *Example:* Probenecid decreases renal clearance of penicillin.

Pharmacodynamic interactions: arise when two drugs influence similar physiological pathways or receptor systems. These interactions may produce additive, synergistic, or antagonistic effects. A common example is the combined use of benzodiazepines and opioids, which can lead to excessive central nervous system depression.

- **Additive or synergistic effects**:
  Example: Opioids + benzodiazepines increase the risk of respiratory depression .

- **Antagonistic effects**:
  Example: NSAIDs may reduce the antihypertensive effect of ACE inhibitors.

Traditional approaches to DDI detection such as clinical trials, manual chart review, and spontaneous reporting often fail to capture rare, complex, or multi-drug interactions.

Several uploaded studies highlight that real-world data, electronic health records, and patient-generated sources are rich in signals but difficult to analyse manually. This limitation is one reason AI-driven tools are being explored to predict DDIs earlier and more accurately.

- **Clinical Importance of DDIs:**

1. Reduced therapeutic response
2. Increased toxicity or life-threatening events
3. Prolonged hospitalization
4. Need for additional treatment
5. Increased healthcare expenditure

Elderly patients, individuals with chronic diseases, and those on complex therapeutic regimens are especially vulnerable

- **Challenges in Identifying DDIs**

Traditional detection approaches often fail to capture complex or rare DDIs due to:

1. Underreporting in spontaneous reporting systems
2. Limited sample sizes in clinical trials
3. Unrecognized interactions involving herbal or over-the-counter products



Fig-3: Overview of AI techniques used in DDIs

4. AI Techniques for DDI Prediction

Artificial Intelligence (AI) has emerged as a powerful approach for predicting drug–drug interactions (DDIs), offering the ability to identify complex patterns that traditional pharmacovigilance systems often miss. As healthcare datasets expand in volume and complexity including chemical structures, biological pathways, electronic health records (EHRs), and post-marketing safety reports AI techniques provide more accurate, scalable, and timely methods for DDI detection.

I] Machine Learning (ML) Approaches

Traditional ML algorithms such as **Support Vector Machines (SVMs), Random Forests (RF), Gradient Boosting models, and Logistic Regression** are widely used for DDI prediction. These models learn from structured datasets that include drug properties, pharmacokinetic variables, molecular descriptors, and known interaction pairs.

- **Random Forests** capture nonlinear relationships and are effective when handling noisy pharmacovigilance data.
- **Gradient Boosting** has been shown (in uploaded studies) to outperform several classical models when predicting ADRs and DDIs from EHR data because of its strong ability to integrate diverse features.
- **SVMs** are commonly applied in chemical similarity–based DDI prediction models.

II] Deep Learning (DL) Techniques

Deep learning methods have transformed DDI research by modelling high-dimensional drug data without requiring manual feature engineering.

- **Convolutional Neural Networks (CNNs)**

CNNs extract hierarchical patterns from drug chemical structures, fingerprints, and side-effect profiles. Studies show that CNN models achieve high predictive accuracy (AUC > 0.90) when analysing patient-generated content and molecular representations.

- **Recurrent Neural Networks (RNNs) & LSTM Models**

LSTM networks capture sequential dependencies, making them ideal for analyzing:

a. clinical narratives,

b. temporal EHR data

c. long-term patient histories

- **Autoencoders**

Used for dimensionality reduction and uncovering hidden associations between drug features. They support unsupervised DDI discovery.

III] Graph-Based Models and Graph Neural Networks (GNNs)

- **Graph Neural Networks (GNNs)** treat drugs as nodes and interactions as edges, enabling prediction of new links (unknown DDIs).
- **Knowledge graph models** integrate chemical, genomic, and pharmacological relationships into a unified network.



Fig-4: AI techniques for Prediction

IV] Natural Language Processing (NLP)

NLP extracts DDI information from:

- biomedical literature,
- clinical notes,
- social media posts,
- pharmacovigilance databases.

V] Hybrid and Integrative AI Models

Newer models combine ML/DL methods with mechanistic pharmacology:

- **AI + Systems Biology** integrates metabolic pathways and protein–drug interactions.
- **AI + Pharmacokinetics (PBPK models)** predicts exposure-based DDIs.
- **Ensemble models** merge multiple AI outputs to improve robustness.

These hybrid systems support personalized DDI prediction based on patient-specific biological or genomic factors.

5. Data Sources for AI-Based DDI Prediction

1. Chemical and Pharmacological Databases

Databases containing chemical structures, molecular descriptors, and pharmacological properties are essential for machine learning and deep learning models.

- **DrugBank:** Provides detailed chemical structures, drug targets, mechanisms, and known interactions. It is one of the most frequently used datasets in DDI prediction research.
- **KEGG (Kyoto Encyclopedia of Genes and Genomes):** Offers pathway information that helps AI models understand drug metabolism, enzyme interactions, and biological networks.
- **ChEMBL:** Includes bioactivity data and molecular fingerprints used for similarity-based DDI prediction

2. Side-Effect and Adverse Reaction Databases

AI systems often use side-effect profiles to infer unknown DDIs because drugs that share adverse events may interact pharmacologically.

- **SIDER:** Contains detailed drug–side effect relationships, useful for ADR-based DDI inference.
- **TWOSIDES:** A large database of statistically derived drug–drug side-effect associations generated from patient data.

3. Pharmacogenomic and Molecular Biology Databases

Genomic factors influence how drugs are metabolized and how interactions occur. AI models increasingly integrate these datasets to support personalized DDI prediction.

- **PharmGKB:** Provides data on gene–drug interactions, metabolic enzymes, and genetic variants that affect drug responses.
- **Protein–protein interaction datasets (e.g., STRING):** Support graph-based models in mapping biological mechanisms underlying DDIs.

5. Biomedical Literature and Unstructured Text Sources

Natural Language Processing (NLP) extracts interaction signals from research articles, clinical reports, and patient-generated content.

- **PubMed/MEDLINE:** The primary source for extracting novel DDIs from biomedical literature.
- **Clinical notes:** Provide real-world observations that may not be captured in structured databases.
- **Social media and patient forums:** Offer early warnings about potential interaction effects.

Transformer models such as BioBERT, SciBERT, and ClinicalBERT are widely used for mining these text sources.

6. Integrated Knowledge Graphs and Multi-Omics Repositories

Advanced AI systems combine several datasets into knowledge graphs, linking:

- drugs
- proteins,
- metabolic pathways,
- diseases, and ADR profiles.

Database	Description	Used in DDI Prediction
Pubmed/MEDLINE	Biomedical literature	NLP-based text minig
DrugBank	Chemical and pharmacological data	Primary dataset for training
KEGG	Pathway and metabolic networks	Mechanistic DDI prediction
TWOSIDES	Drug–drug side effect associations	Used for deep learning models
SIDER	Drug side effect and ADR data	Toxicity-based DDI prediction
PharmGKB	Pharmacogenomic data	Personalized DDI prediction
FAERS	FDA adverse event reports	Post-marketing surveillance

Table-1

6. Case Studies and Applications

Artificial Intelligence has significantly advanced the prediction, detection, and management of Drug–Drug Interactions (DDIs). Multiple real-world case studies demonstrate how machine learning, deep learning, graph-based systems, and natural language processing (NLP) models enhance pharmacovigilance and clinical decision-making

❖ **DeepDDI: AI-Based Structural Prediction of DDIs:**

One of the most cited AI models, **DeepDDI**, uses deep neural networks trained on drug chemical structures to estimate more than 80 different types of drugs–drug interaction outcomes. This model demonstrated high predictive performance (AUC > 0.93), proving that molecular fingerprints and deep learning can uncover previously unknown DDIs with high reliability.

Application:

- Screening new drugs for interaction risks
- Prioritizing compounds during early drug development

❖ **Graph Neural Networks (GNNs) for Polypharmacy Risk Modeling:**

GNN-based systems treat drugs and biological entities as nodes in a large network. A landmark study used **Graph Convolutional Networks (GCNs)** to predict polypharmacy side effects among thousands of drug combinations.
This method was particularly useful in identifying interactions caused by shared targets or metabolic pathways.
Application:

- Predicting side effects from combinations of ≥ 2 drugs
- Modeling large, complex drug networks not manageable manually

❖ **NLP-Based DDI Extraction from Biomedical Literature:**

Models based on **BioBERT, SciBERT, and ClinicalBERT** have been used to automatically extract interaction information from millions of PubMed articles.
These systems achieved high F1-scores in the DDIExtraction challenge, proving that AI can mine textual data faster and more accurately than manual review.
Application:

- Early detection of newly reported DDIs
- Automated updating of drug interaction databases

❖ **AI-Enhanced Pharmacovigilance in Regulatory Settings:**

Regulatory bodies and pharmacovigilance centers have explored AI for real-time DDI signal detection. For example, machine learning models applied to **FAERS** and **VigiBase** have shown improved capability to detect unexpected interaction patterns by learning co-reporting trends and ADR signatures.
Application:

- Post-marketing safety analysis
- Identifying rare and previously unrecognized DDIs

7.Advantages of AI in DDI Prediction

Artificial Intelligence (AI) provides several important benefits in predicting Drug–Drug Interactions (DDIs), making it a valuable tool for strengthening drug safety and pharmacovigilance practices. Unlike traditional methods, which rely mainly on manual reporting and limited clinical data, AI systems can analyse vast and diverse datasets to detect hidden patterns associated with potential interactions. This enables earlier, more accurate identification of harmful drug combinations. One major advantage of AI is its ability to process large and complex datasets, including chemical structures, genomic information, electronic health records, and adverse event databases. Machine learning and deep learning models can integrate these heterogeneous sources to produce highly accurate DDI predictions.

a) Early and Accurate Detection of Interactions

AI models can identify potential DDIs long before they appear through clinical reports or spontaneous reporting systems.
Machine learning and deep learning algorithms learn subtle relationships from chemical structures, biological networks, and real-world patient data, enabling accurate prediction of both known and previously unrecognized interactions

b) Improved Detection of Rare and Complex DDIs

Traditional methods struggle with rare interactions or those involving multiple drugs (polypharmacy). AI models, especially graph neural networks (GNNs) and ensemble systems, are capable of detecting rare patterns and multi-drug interactions by leveraging high-dimensional patient and drug data.

c) Enhanced Predictive Performance

Deep learning models such as CNNs, LSTMs, and GNNs consistently outperform rule-based and statistical approaches.
These models show superior performance in metrics like AUC-ROC, sensitivity, and F1 score, leading to more reliable DDI predictions.

d) Real-Time Clinical Decision Support

AI-enhanced systems embedded in electronic health records (EHRs) generate real-time DDI alerts during prescribing or dispensing.
This reduces medication errors, enhances patient safety, and supports clinicians with timely, data-driven recommendations.



Fig-5: Advantages of AI in DDI Prediction

8. Limitations and Challenges

Despite its growing importance in pharmacovigilance, Artificial Intelligence (AI) still faces several limitations and challenges in accurately predicting Drug–Drug Interactions (DDIs). These issues must be addressed to ensure that AI-driven models are reliable, transparent, and suitable for clinical use.

Data Quality Issues

- AI models depend on high-quality datasets, but many sources (EHRs, FAERS, literature) contain missing values, noise, and reporting inconsistencies.
- Underreporting in spontaneous reporting systems leads to incomplete learning and potential false predictions.

Algorithmic Bias

- Training data may reflect demographic, clinical, or regional biases that influence model outputs.
- Models may perform poorly for underrepresented populations or rare drug combinations.

Lack of Model Transparency

- Deep learning models such as CNNs, LSTMs, and GNNs often function as "black boxes."
- Limited interpretability makes it difficult for clinicians and regulators to trust or validate predictions.

Data Integration Challenges

- Drug safety data originates from diverse sources (chemical, genomic, clinical, textual), often using incompatible coding schemes.
- Standardizing terminology, merging formats, and harmonizing datasets requires extensive preprocessing

Limited Clinical Validation

- Many AI models perform well in controlled studies but lack testing in real-world clinical settings.
- This limits generalizability and slows adoption into decision-support systems.



Fig no 5. Limitations and Challenges of AI in DDIs

9. Future Directions

As Artificial Intelligence continues to evolve, several promising research directions are expected to strengthen Drug–Drug Interaction (DDI) prediction and make AI-driven pharmacovigilance more accurate, transparent, and clinically useful

1. **Integration of Multi-Omics and Personalized Data**

- Incorporating genomics, proteomics, metabolomics, and microbiome data can enable individualized DDI risk predictions.
- Personalized models will help tailor drug regimens to a patient's genetic makeup and physiological characteristics.

2. **Use of Federated Learning for Privacy-Preserving Collaboration**

- Federated learning will allow hospitals, regulators, and research centers to train models on decentralized datasets without sharing raw patient data.

3. **More Advanced Graph-Based and Network Model**

- Future research may adopt dynamic graph neural networks (GNNs) to model evolving medication patterns and time-dependent interactions.
- Knowledge graphs combining drugs, proteins, metabolic pathways, and ADRs will improve mechanistic understanding.

4. **AI Integration into Real-Time Clinical Decision Support Systems**

  - Embedding AI models directly into electronic prescribing tools will provide real-time DDI alerts tailored to patient history, lab values, and risk factors.
  - This will reduce medication errors and improve point-of-care decision-making.

5. **Improved Standardization and Regulatory Frameworks**

  - Establishing standardized datasets, validation metrics, and transparent reporting guidelines will make DDI prediction models more reliable.
  - Regulatory authorities are expected to introduce specific policies supporting the safe and ethical use of AI in pharmacovigilance.

6. **Large-Scale Prospective Clinical Validation**

- Future research must test AI models in real clinical environments to validate their safety and performance.
- Prospective trials and real-world evaluations will determine clinical utility and improve model robustness.

7. **Integration Into Smart Prescribing Platforms**

AI-powered systems will be built directly into electronic prescribing tools so that physicians receive intelligent DDI alerts based on

- patient history
- lab values
- comorbidities



Fig no 6. Future directions of AI in DDI

10. Conclusion

Artificial Intelligence has emerged as a transformative tool in modern pharmacovigilance, offering new possibilities for predicting Drug-Drug Interactions (DDIs) with greater speed, accuracy, and depth than traditional methods.

By integrating diverse datasets including chemical structures, clinical records, adverse event reports, and biomedical literature AI-driven models can identify complex interaction patterns that might otherwise remain undetected. Advances in machine learning, deep learning, natural language processing, and network-based approaches have contributed to more reliable screening of potential DDIs, supporting safer prescribing practices and improving patient outcomes. Although AI demonstrates substantial potential, its successful application depends on overcoming challenges related to data quality, model interpretability, algorithmic bias, and clinical validation.

Addressing these limitations is crucial for ensuring that AI-driven tools are transparent, trustworthy, and clinically acceptable. Continued improvements in explainable AI, standardized datasets, federated learning frameworks, and integrated clinical decision support systems are expected to drive the next generation of predictive pharmacovigilance.

Overall, AI represents a significant advancement toward proactive, personalized, and efficient drug safety monitoring. Its expanding role in DDI prediction not only enhances

References :

1) Paliwal, D., & Sharma, A. (2020). Role of AI and ML in predicting drug interactions. Indian J Pharm Sci.

2) Wang, Y., et al. (2021). Multi-omics integration for DDI prediction. Brief Bioinform.

3) Kim, J., & Park, S. (2023). Deep learning in pharmacovigilance. Front AI.

4) Liang, Y., et al. (2024). Explainable AI for drug safety and DDI prediction. Trends Pharmacol Sci.

5) Barde, V.G., et al. *Artificial Intelligence in Pharmacovigilance: Practical Utility.* IJSDR, 2025. (Discusses AI tools, ML/NLP uses in PV, processing of large datasets)

6) Kumar, V.S., et al. *Next-Generation Pharmacovigilance – The Role of AI in ADR Monitoring.*IJCRT,2025. (Details rising complexity of drug therapy, limitations of traditional PV, AI advantages)

7) Pramanik, A., et al. *The Role of AI in Predicting Adverse Drug Reactions: Enhancing Patient Safety.* JPTCP, 2024.
(Shows ML/DL model performance in ADR prediction; supports claim that AI identifies hidden patterns early)

8) Nagar, A., et al. *Artificial Intelligence in Pharmacovigilance: Advancing Drug Safety Monitoring and Regulatory Integration.* Therapeutic Advances in Drug Safety, 2025.
(Discusses historical evolution of AI in PV and its superiority over traditional methods)

9) World Health Organization. *Benefits and Risks of Using Artificial Intelligence for Pharmaceutical Development and Delivery.* WHO, 2024.
(Provides global perspective on AI's role in drug development and safety)

10) Barde, V.G., et al. "Artificial Intelligence in Pharmacovigilance: Practical Utility." *International Journal of Scientific Development and Research*, 2025.

11) Kumar, V.S., et al. "Next-Generation Pharmacovigilance – The Role of AI in Adverse Drug Reaction Monitoring." *IJCRT*, 2025.

12) Priya, T., et al. "Role of AI in Pharmacovigilance and Drug Safety: A Review." *IJIRT*, 2025.

13) Jaiswal, R. *The Role of Artificial Intelligence in Advancing Pharmacovigilance Systems.* 2025.

14) Pramanik, A., et al. "The Role of AI in Predicting Adverse Drug Reactions: Enhancing Patient Safety." *JPTCP*, 2024.

15) Nagar, A., et al. "Artificial Intelligence in Pharmacovigilance: Advancing Drug Safety Monitoring and Regulatory Integration." *Therapeutic Advances in Drug Safety*, 2025
Baxter, K., & Preston, C.L. (Eds.). (2020). Stockley's Drug Interactions (12th ed.). Pharmaceutical Press.

16) Brunton, L., Hilal-Dandan, R., & Knollmann, B. (2018). Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill

17) U.S. Food and Drug Administration (FDA). (2016). FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid medications with benzodiazepines.

18) Maher, R.L., Hanlon, J., & Hajjar, E.R. (2014). Clinical consequences of polypharmacy in elderly. *Expert Opinion on Drug Safety*, 13(1), 57–65.

19) Qato, D.M., et al. (2008). Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. *JAMA*, 300(24), 2867–2878.

20) Flockhart, D.A. (2012). Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine

21) Ryu, J. Y., et al. (2018). DeepDDI: A Deep Learning Model for DDI Prediction Using Drug Structure Features. *Bioinformatics*, 34(20), 3457–3464.

22) Zitnik, M., Agrawal, M., & Leskovec, J. (2018). Modeling Polypharmacy Side Effects with Graph Convolutional Networks. *Bioinformatics*, 34(13), i457–i466.

23) Zhang, W., et al. (2017). A Review of Machine Learning Approaches to Drug–Drug Interaction Prediction. *Current Pharmaceutical Design*, 23(7), 1–9.

24) Li, Y., et al. (2020). BioBERT-Based Relation Extraction for Biomedical Literature Mining. *Briefings in Bioinformatics*, 22(4), bbaa047.